Search

Your search keyword '"Taghian, Alphonse G."' showing total 702 results
Start Over Author "Taghian, Alphonse G."
702 results on '"Taghian, Alphonse G."'

3. Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial

Author

Godette, Karen D., Patel, Sagar, Langen, Katja M., Zielan, Ryan R., DeBlois, David, Pang, Dalong, Rudra, Sonali, Benhabib, Sidi, Chawla, Ashish, Chen, Kuanling, Dadkhah, Hossein, Majithia, Lonika, Rao, Avani D., Stephenson, Lisa, Wang, Peng, Croog, Victoria J., Li, Heng, Smith, Karen, Stinson, Susan, Walker, Amanda J., Devisetty, Kiran, Hyde, Christian, Depauw, Nicholas, Godishala, Anuradha, Ho, Alice, Paganetti, Harald, Soto, Daniel, Suero-Abreu, Giselle, Taghian, Alphonse G., Corbin, Kimberly S., Halyard, Michele Y., Jackson, Amanda, Liang, Xiaoying, Manke, Heather, McGee, Lisa A., Pafundi, Deanna H., Remmes, Nicholas B., Shumway, Dean A., Yan, Elizabeth S., Bakhoum, Samuel F., Barron, David A., Bernstein, Michael, Cuaron, John J., Dover, Laura, Gelblum, Daphna Y., Gilbo, Philip, Gewanter, Richard M., Guttman, David M., Hong, Linda, Khan, Atif, LaPlant, Quincey, Mann, Justin, McCormick, Beryl, Mueller, Boris A., Mychalczak, Borys, Parikh, Dhwani, Powell, Simon N., Romesser, Paul B., Roth O'Brien, Diana, Schupak, Karen D., Shepherd, Annemarie F., Xu, Amy, Yu, Anthony, Zinovoy, Melissa, Bennouna, Jaafar, Fagundes, Marcio, Panoff, Joseph, Amelia Rodrigues, Maria, Yu, Jen, Lee, Choonsik, Chen, Chin-Cheng, Choi, J. Isabelle, Lin, Haibo, Akthar, Adil S., Akhter, Nausheen, Mihalcik, Stephen A., Pankuch, Mark, Parhar, Preeti K., Stutz, Michael D., Thukral, Arpi D., Mah, Dennis, Tsai, Henry K., Paulus, Rebecca, Haffty, Bruce G., Goyal, Sharad, Yue, Ning J., Sturgeon, Jared D., Wilkinson, J. Ben, Boggs, D. Hunter, Cardan, Rex A., Dalton, Allison, McDonald, Andrew, Prior, Fred, Mayadev, Jyoti S., Moiseenko, Vitali, Narezkina, Anya, Phreaner, Nicholas, Rash, Dominique, Seibert, Tyler, Yashar, Catheryn, Daugherty, Emily C., Mascia, Anthony, Medek, Sara A., Meier, Teresa, Bradley, Julie A., Lockney, Natalie, Mailhot, Raymond B., Mendenhall, Nancy, Rutenberg, Michael, Harris, Eleanor E., Lyons, Janice, Hong, Jack J., Kunaprayoon, Dan K., McAvoy, Sarah A., Manu Mysore, Nowak Choi, Kamila A., Patel, Akshar N., Vyfhuis, Melissa A.L., Wilson, Joelle, Algan, Ozer, Chen, Yong, Henson, Christina E., Dvorak, Tomas, Willoughby, Twyla, Zeidan, Omar, Berman, Abigail T., Chen, Et-tsu, Dong, Lei, Driscoll, Amanda, Feigenberg, Steven J., Feriozzi, Ashley, Hencek, Carolyn, Kolker, James D., Konski, Andre A., Ky, Bonnie, Lin, Lilie L., Novick, Kristina L., Reza, Nosheen, Siegal, Ann Marie, Tabakha, Sara, Taunk, Neil K., Wilcox, Nicholas, Zou, Wei, Bhooshan, Neha, Croley, Richard, Weksberg, David C., Ahmad, Neelour, Hoffman, Karen E., Joyner, Melissa M., Mitchell, Melissa P., Poenisch, Falk, Smith, Benjamin D., Strom, Eric A., Vallabhaneni, Srilakshmi, Cheng, Richard, Kang, Kylie H., Kim, H. Katherine, Kim, Janice N., Wang, Waylene A., Wong, Tony, Bosch, Walter, Mitchell, Joshua, Straube, William, Zoberi, Imran, Balanescu, Dinu, Chen, Peter Y., Dilworth, Joshua T., Ding, Xuanfeng, Donisan, Teodora, Hamstra, Daniel A., Daniella Dang, Phuong, Katz, Stanford, Wang, Chiachien J., Terry Wu, Hahn, Elizabeth A., Pugh, Stephanie L., Lu, Hien L., Vela, Alyssa M., Gillespie, Erin F., Nichols, Elizabeth M., Wright, Jean L., MacDonald, Shannon M., Cahlon, Oren, Baas, Carole, Braunstein, Lior Z., Fang, L. Christine, Freedman, Gary M., Jimenez, Rachel B., Kesslering, Christy M., Mishra, Mark V., Mutter, Robert W., Ohri, Nisha, Rosen, Lane R., Urbanic, James J., Jagsi, Reshma, Mitchell, Sandra A., Bekelman, Justin E., and Cella, David

Published
2024
Full Text
View/download PDF

5. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment

Author

Wang, Yufeng, Drum, David L., Sun, Ruochuan, Zhang, Yida, Chen, Feng, Sun, Fengfei, Dal, Emre, Yu, Ling, Jia, Jingyu, Arya, Shahrzad, Jia, Lin, Fan, Song, Isakoff, Steven J., Kehlmann, Allison M., Dotti, Gianpietro, Liu, Fubao, Zheng, Hui, Ferrone, Cristina R., Taghian, Alphonse G., DeLeo, Albert B., Ventin, Marco, Cattaneo, Giulia, Li, Yongxiang, Jounaidi, Youssef, Huang, Peigen, Maccalli, Cristina, Zhang, Hanyu, Wang, Cheng, Yang, Jibing, Boland, Genevieve M., Sadreyev, Ruslan I., Wong, LaiPing, Ferrone, Soldano, and Wang, Xinhui

Published
2023
Full Text
View/download PDF

6. Weight loss does not decrease risk of breast cancer-related arm lymphedema.

Author

Roberts, Sacha A, Gillespie, Tessa C, Shui, Amy M, Brunelle, Cheryl L, Daniell, Kayla M, Locascio, Joseph J, Naoum, George E, and Taghian, Alphonse G

Subjects
Humans, Breast Neoplasms, Lymphedema, Weight Loss, Cohort Studies, Female, Breast Cancer Lymphedema, breast cancer, breast cancer-related lymphedema, lymphedema, weight change, Prevention, Cancer, Clinical Research, Breast Cancer, Good Health and Well Being, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe goal of this study was to determine the relationship between postoperative weight change and breast cancer-related lymphedema (BCRL).MethodsIn this cohort study, 1161 women underwent unilateral breast surgery for breast cancer from 2005 to 2020 and were prospectively screened for BCRL. Arm volume measurements were obtained via an optoelectronic perometer preoperatively, postoperatively, and in the follow-up setting every 6 to 12 months. Mean follow-up from preoperative baseline was 49.1 months. The main outcome was BCRL, defined as a relative volume change of the ipsilateral arm of ≥10% at least 3 months after surgery.ResultsA total of 92 patients (7.9%) developed BCRL. Net weight loss versus net weight gain from baseline to last follow-up was not protective against developing BCRL (hazard ratio, 1.38; 95% confidence interval, 0.89-2.13; P = .152).ConclusionsAlthough weight loss may be recommended as part of an individualized lifestyle management program for overall health, weight loss alone may not decrease the risk of developing BCRL.

Published
2021

8. Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer-Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial.

Author

Naoum, George E, Roberts, Sacha, Brunelle, Cheryl L, Shui, Amy M, Salama, Laura, Daniell, Kayla, Gillespie, Tessa, Bucci, Loryn, Smith, Barbara L, Ho, Alice Y, and Taghian, Alphonse G

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Prevention, Patient Safety, Clinical Research, Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Adult, Aged, Aged, 80 and over, Breast Cancer Lymphedema, Breast Neoplasms, Cohort Studies, Female, Humans, Incidence, Lymph Node Excision, Lymph Nodes, Lymphatic Metastasis, Middle Aged, Prospective Studies, Radiotherapy, Randomized Controlled Trials as Topic, Young Adult, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeTo independently evaluate the impact of axillary surgery type and regional lymph node radiation (RLNR) on breast cancer-related lymphedema (BCRL) rates in patients with breast cancer.Patients and methodsFrom 2005 to 2018, 1,815 patients with invasive breast cancer were enrolled in a lymphedema screening trial. Patients were divided into the following 4 groups according to axillary surgery approach: sentinel lymph node biopsy (SLNB) alone, SLNB+RLNR, axillary lymph node dissection (ALND) alone, and ALND+RLNR. A perometer was used to objectively assess limb volume. All patients received baseline preoperative and follow-up measurements after treatment. Lymphedema was defined as a ≥ 10% relative increase in arm volume arising > 3 months postoperatively. The primary end point was the BCRL rate across the groups. Secondary end points were 5-year locoregional control and disease-free-survival.ResultsThe cohort included 1,340 patients with SLNB alone, 121 with SLNB+RLNR, 91 with ALND alone, and 263 with ALND+RLNR. The overall median follow-up time after diagnosis was 52.7 months for the entire cohort. The 5-year cumulative incidence rates of BCRL were 30.1%, 24.9%, 10.7%, and 8.0% for ALND+RLNR, ALND alone, SLNB+RLNR, and SLNB alone, respectively. Multivariable Cox models adjusted for age, body mass index, surgery, and reconstruction type showed that the ALND-alone group had a significantly higher BCRL risk (hazard ratio [HR], 2.66; P = .02) compared with the SLNB+RLNR group. There was no significant difference in BCRL risk between the ALND+RLNR and ALND-alone groups (HR, 1.20; P = .49) and between the SLNB-alone and SLNB+RLNR groups (HR, 1.33; P = .44). The 5-year locoregional control rates were similar for the ALND+RLNR, ALND-alone, SLNB+RLNR, and SLNB-alone groups (2.8%, 3.8%, 0%, and 2.3%, respectively).ConclusionAlthough RLNR adds to the risk of lymphedema, the main risk factor is the type of axillary surgery used.

Published
2020

13. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer

Author

Bellon, Jennifer R., Chen, Yu-Hui, Rees, Rebecca, Taghian, Alphonse G., Wong, Julia S., Punglia, Rinaa S., Shiloh, Ron Y., Warren, Laura E.G., Krishnan, Monica S., Phillips, John, Pretz, Jennifer, Jimenez, Rachel, Macausland, Stephanie, Pashtan, Itai, Andrews, Chelsea, Isakoff, Steven J., Winer, Eric P., and Tolaney, Sara M.

Published
2021
Full Text
View/download PDF

14. Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers

Author

Russo, Sandra, Walker, Joan L., Carlson, Jay W., Carter, Jeanne, Ward, Leigh C., Covens, Allan, Tanner, Edward J., III, Armer, Jane M., Ridner, Sheila, Hayes, Sandi, Taghian, Alphonse G., Brunelle, Cheryl, Lopez-Acevedo, Micael, Davidson, Brittany A., Schaverien, Mark V., Ghamande, Sharad A., Bernas, Michael, Cheville, Andrea L., Yost, Kathleen J., Schmitz, Kathryn, Coyle, Barbara, Zucker, Jeannette, Enserro, Danielle, Pugh, Stephanie, Paskett, Electra D., Ford, Leslie, and McCaskill-Stevens, Worta

Published
2021
Full Text
View/download PDF

15. Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer

Author

Greenup, Rachel A, Blitzblau, Rachel C, Houck, Kevin L, Sosa, Julie Ann, Horton, Janet, Peppercorn, Jeffrey M, Taghian, Alphonse G, Smith, Barbara L, and Hwang, E Shelley

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Breast Cancer, Health Services, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Breast Neoplasms, Costs and Cost Analysis, Dose Fractionation, Radiation, Evidence-Based Practice, Female, Health Care Costs, Humans, Mastectomy, Segmental, Middle Aged, Neoplasm Grading, Neoplasm Staging, Postoperative Care, Radiotherapy Dosage, Radiotherapy, Adjuvant, Tumor Burden, Young Adult, Oncology & Carcinogenesis
Abstract

IntroductionBreast cancer treatment costs are rising, and identification of high-value oncology treatment strategies is increasingly needed. We sought to determine the potential cost savings associated with an evidence-based radiation treatment (RT) approach among women with early-stage breast cancer treated in the United States.Patients and methodsUsing the National Cancer Database, we identified women with T1-T2 N0 invasive breast cancers treated with lumpectomy during 2011. Adjuvant RT regimens were categorized as conventionally fractionated whole-breast irradiation, hypofractionated whole-breast irradiation, and omission of RT. National RT patterns were determined, and RT costs were estimated using the Medicare Physician Fee Schedule.ResultsWithin the 43,247 patient cohort, 64% (n = 27,697) received conventional RT, 13.3% (n = 5,724) received hypofractionated RT, 1.1% (n = 477) received accelerated partial-breast irradiation, and 21.6% (n = 9,349) received no RT. Among patients who were eligible for shorter RT or omission of RT, 57% underwent treatment with longer, more costly regimens. Estimated RT expenditures of the national cohort approximated $420.2 million during 2011, compared with $256.2 million had women been treated with the least expensive regimens for which they were safely eligible. This demonstrated a potential annual savings of $164.0 million, a 39% reduction in associated treatment costs.ConclusionAmong women with early-stage breast cancer after lumpectomy, use of an evidence-based approach illustrates an example of high-value care within oncology. Identification of high-value cancer treatment strategies is critically important to maintaining excellence in cancer care while reducing health care expenditures.

Published
2017

20. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA

Author

Jagsi, Reshma, primary, Griffith, Kent A., additional, Harris, Eleanor E., additional, Wright, Jean L., additional, Recht, Abram, additional, Taghian, Alphonse G., additional, Lee, Lucille, additional, Moran, Meena S., additional, Small, William, additional, Johnstone, Candice, additional, Rahimi, Asal, additional, Freedman, Gary, additional, Muzaffar, Mahvish, additional, Haffty, Bruce, additional, Horst, Kathleen, additional, Powell, Simon N., additional, Sharp, Jody, additional, Sabel, Michael, additional, Schott, Anne, additional, and El-Tamer, Mahmoud, additional

Published
2023
Full Text
View/download PDF

27. Integrating Symptoms Into the Diagnostic Criteria for Breast Cancer-Related Lymphedema: Applying Results From a Prospective Surveillance Program

Author

Brunelle, Cheryl L., Roberts, Sacha A., Horick, Nora K., Gillespie, Tessa C., Jacobs, Jamie M., Daniell, Kayla M., Naoum, George E., and Taghian, Alphonse G.

Subjects
Sentinel health events -- Methods, Lymphedema -- Distribution -- Diagnosis, Breast cancer -- Distribution -- Diagnosis, Company distribution practices, Health
Abstract

Objective. The objectives of this study were to determine whether patients reporting symptoms are more likely to develop lymphedema and to describe the temporal relationship between symptom onset and lymphedema. Methods. This was a prospective longitudinal cohort study of 647 women treated for breast cancer and screened for lymphedema using arm volume measurements and subjective questionnaires (n = 647; 2284 questionnaires [median 3.5 per patient, range = 1-24]). Primary study outcome was lymphedema (relative volume change [greater than or equal to]10%). The Kaplan-Meier method was used to estimate cumulative lymphedema incidence. Cox proportional hazards models were used to assess the relationship between symptoms, other risk factors, and lymphedema. Results. A total of 64 patients (9.9%) developed lymphedema. On multivariable analysis, patients reporting increased arm size (hazard ratio = 3.09, 95% CI = 1.62-5.89) were more likely to progress to lymphedema than those who did not report this symptom. Of those who developed lymphedema, 37 (58%) reported an increased arm size a median of 6.1 months before lymphedema onset (range = 68.6 months before to 50.2 months after lymphedema onset). Conclusion. Patients at risk of lymphedema who report increased arm size might do so prior to lymphedema onset and are at 3 times the risk of lymphedema as patients not reporting this symptom. Even without objective or observable edema, these patients should be followed vigilantly and considered for early intervention. Symptoms should be incorporated into screening and diagnostic criteria for lymphedema. Impact. This study shows that patients at risk for breast cancer-related lymphedema who report increased arm size should be considered at high risk for progression to lymphedema--even without edema on measurement or clinical examination--and should be followed vigilantly, with consideration of early intervention., Lay summary. If you are at risk of lymphedema and you feel as though your arm size has increased, you might develop lymphedema, and you are at 3 times the [...]

Published
2020

29. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA.

Author

Jagsi, Reshma, Griffith, Kent A., Harris, Eleanor E., Wright, Jean L., Recht, Abram, Taghian, Alphonse G., Lee, Lucille, Moran, Meena S., Small Jr, William, Johnstone, Candice, Rahimi, Asal, Freedman, Gary, Muzaffar, Mahvish, Haffty, Bruce, Horst, Kathleen, Powell, Simon N., Sharp, Jody, Sabel, Michael, Schott, Anne, and El-Tamer, Mahmoud

Published
2024
Full Text
View/download PDF

33. Accelerated Partial Breast Irradiation

Author

Sanford, Nina N., Taghian, Alphonse G., Veronesi, Umberto, editor, Goldhirsch, Aron, editor, Veronesi, Paolo, editor, Gentilini, Oreste Davide, editor, and Leonardi, Maria Cristina, editor

Published
2017
Full Text
View/download PDF

34. Reply to G.B. Mann et al and S. Sorscher.

Author

Jagsi, Reshma, Griffith, Kent A., Harris, Eleanor E., Wright, Jean L., Recht, Abram, Taghian, Alphonse G., Lee, Lucille, Moran, Meena S., Small Jr, William, Johnstone, Candice, Rahimi, Asal, Freedman, Gary, Muzaffar, Mahvish, Haffty, Bruce, Horst, Kathleen, Powell, Simon N., Sharp, Jody, Sabel, Michael, Schott, Anne, and El-Tamer, Mahmoud

Published
2024
Full Text
View/download PDF

45. Abstract OT2-09-01: TBCRC-055: A Phase II Study of NirAparib, Dostarlimab, and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR) – NCT04837209

Author

Scott, Elizabeth, primary, Isakoff, Steven J., additional, Taghian, Alphonse G., additional, Wright, Jean, additional, Santa-Maria, Cesar Augusto, additional, Shah, Payal, additional, Taunk, Neil, additional, Anders, Carey, additional, Blitzblau, Rachel, additional, Gupta, Gaorav, additional, and Ho, Alice, additional

Published
2023
Full Text
View/download PDF

48. Abstract OT3-15-01: TBCRC-053: P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer

Author

Connolly, Joseph J., primary, Spring, Laura M., additional, Taghian, Alphonse G., additional, Gadd, Michele, additional, Warren, Laura, additional, Garrido-Castro, Ana C., additional, King, Tari, additional, Mittendorf, Elizabeth A., additional, Leone, Jose P., additional, Casey, Dana L., additional, Carey, Lisa, additional, Traina, Tiffany A., additional, Abdou, Yara, additional, Khan, Atif, additional, Plitas, George, additional, Wright, Jean, additional, Santa-Maria, Cesar Augusto, additional, Jacobs, Lisa, additional, Blitzblau, Rachel, additional, Hwang, E Shelley, additional, Anders, Carey, additional, Krop, Ian, additional, Wolff, Antonio C., additional, Thompson, Alastair M., additional, Denault, Elyssa, additional, Gupta, Gaorav, additional, and Ho, Alice, additional

Published
2023
Full Text
View/download PDF

49. Abstract P6-03-04: Ipsilateral infusions are not associated with increased risk of breast cancer-related lymphedema in patients enrolled in a prospective screening program

Author

Brunelle, Cheryl L., primary, Jung, Amanda W., additional, Smith, Louisa H., additional, Daniell, Kayla, additional, Asdourian, Maria S., additional, Bucci, Loryn K., additional, Juhel, Brooke, additional, Hausman, Elizabeth K., additional, Naoum, George E., additional, and Taghian, Alphonse G., additional

Published
2023
Full Text
View/download PDF

50. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors

Author

Wang, Yufeng, primary, Drum, David L., additional, Sun, Ruochuan, additional, Zhang, Yida, additional, Yu, Ling, additional, Jia, Lin, additional, Isakoff, Steven J, additional, Kehlmann, Allison M, additional, Dal, Ali Emre, additional, Dotti, Gianpietro, additional, Zheng, Hui, additional, Ferrone, Cristina R, additional, Taghian, Alphonse G, additional, DeLeo, Albert B, additional, Zhang, Hanyu, additional, Jounaidi, Youssef, additional, Fan, Song, additional, Huang, Peigen, additional, Wang, Cheng, additional, Yang, Jibing, additional, Boland, Genevieve M, additional, Sadreyev, Ruslan I, additional, Wong, LaiPing, additional, Ferrone, Soldano, additional, and Wang, Xinhui, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results